Clinical Trial Update: Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a vaccine therapy for HLA-A2 positive melanoma patients has completed enrollment and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• HLA-A2 melanoma vaccine

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Melanoma, Stage IA Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2017-02-20